TEVA-AMPHETAMINE XR 25 MG
MIXED SALTS AMPHETAMINE : 25 MG · DIN 02439271 · TEVA CANADA LIMITED
Health Canada status: MARKETED
What is TEVA-AMPHETAMINE XR?
TEVA-AMPHETAMINE XR 25 MG contains MIXED SALTS AMPHETAMINE : 25 MG. It is listed in the Health Canada Drug Product Database under DIN 02439271, held by TEVA CANADA LIMITED, supplied as CAPSULE (EXTENDED RELEASE) for ORAL administration. Health Canada currently lists it as marketed, status dated 25-Oct-2021. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02439271 |
|---|---|
| Brand name | TEVA-AMPHETAMINE XR |
| Generic / active ingredient | MIXED SALTS AMPHETAMINE : 25 MG |
| Manufacturer | TEVA CANADA LIMITED |
| Strength | 25 MG |
| Dosage form | CAPSULE (EXTENDED RELEASE) |
| Route of administration | ORAL |
| Schedule | CONTROLLED DRUGS (CDSA I) |
| ATC code | N06BA01 AMFETAMINE |
| AHFS class | 28:20.04 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 25-Oct-2021 |
| Original market date | 2015-10-02 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code N06BA01 AMFETAMINE. 22 of 41 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ADDERALL XR | 10 MG | CAPSULE (EXTENDED RELEASE) | TAKEDA CANADA INC | MARKETED | DIN 02248809 |
| ADDERALL XR | 15 MG | CAPSULE (EXTENDED RELEASE) | TAKEDA CANADA INC | MARKETED | DIN 02248810 |
| ADDERALL XR | 20 MG | CAPSULE (EXTENDED RELEASE) | TAKEDA CANADA INC | MARKETED | DIN 02248811 |
| ADDERALL XR | 25 MG | CAPSULE (EXTENDED RELEASE) | TAKEDA CANADA INC | MARKETED | DIN 02248812 |
| ADDERALL XR | 30 MG | CAPSULE (EXTENDED RELEASE) | TAKEDA CANADA INC | MARKETED | DIN 02248813 |
| ADDERALL XR | 5 MG | CAPSULE (EXTENDED RELEASE) | TAKEDA CANADA INC | MARKETED | DIN 02248808 |
| APO-AMPHETAMINE XR | 10 MG | CAPSULE (EXTENDED RELEASE) | APOTEX INC | MARKETED | DIN 02445506 |
| APO-AMPHETAMINE XR | 15 MG | CAPSULE (EXTENDED RELEASE) | APOTEX INC | MARKETED | DIN 02445514 |
| APO-AMPHETAMINE XR | 20 MG | CAPSULE (EXTENDED RELEASE) | APOTEX INC | MARKETED | DIN 02445522 |
| APO-AMPHETAMINE XR | 25 MG | CAPSULE (EXTENDED RELEASE) | APOTEX INC | MARKETED | DIN 02445530 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.